MarketBeacon Report
Mining and Minerals · 13 November 2026

Washington wants American antimony. Here's why it matters

China controls supply, the Pentagon is stockpiling, and the US has one smelter. Here's what the market is telling us, and where new supply could come from.

Pale eroded cliffs above sagebrush in Okanogan County, Washington
Cliffs near Nighthawk in Okanogan County, Washington, the county that is home to the historic Bales antimony mine. Photo: A. Balet / Wikimedia Commons, CC BY 3.0

Antimony is one of those metals most investors never think about. Washington is thinking about it a lot, and that is starting to show up in the money, the rules and the companies trying to fill the gap.

Why antimony matters

Antimony goes into ammunition, flame retardants and batteries. China dominates global supply and has restricted exports, and the US has just one antimony smelter, run by United States Antimony in Montana. For a metal the military depends on, that is an uncomfortable position to be in.

Washington is putting money behind it

The Defense Logistics Agency recently committed US$2 billion to buy strategic materials for the national stockpile. From 1 January 2027, defence contractors are meant to stop sourcing certain critical materials from China and Russia, according to Fortune. And advisers who help companies win federal funding told MINING.COM they expect support to continue whoever controls Congress, because cutting reliance on China has backing from both parties.

What the market is telling us

United States Antimony, the sector's benchmark, is selling more metal than ever: 468,842 pounds last quarter, up 68%, with October its biggest month on record. Prices have been volatile, with its average selling price down about a third on a year ago, which shows how much this market still moves with China's export policy.

The takeaway: demand from Washington is real, and new US supply is scarce. That gap is where the opportunity, and the risk, sits.

Where new supply could come from

That scarcity is why small explorers with American antimony projects are getting attention. One that caught our eye is Krait Critical Minerals (CSE: KRIT, FSE: U0S).

  • A project that has already produced. In September Krait acquired Nevada Hills Antimony LLC, giving it contractual interests in the Bales and Antimony Bell projects in Washington State. Bales was mined in 1951 and 1952, the last time the US scrambled for domestic antimony.
  • Picked out by the state at the time. A 1951 state survey of 37 antimony occurrences named Bales as one of only three with a real chance of commercial production.
  • Encouraging grades. Historical samples reported around 10.9% to 14.4% antimony with low arsenic of about 0.2%, which can mean little processing before a smelter will accept the material.
  • A tight share structure. About 16.1 million shares, no warrants and more than 70% closely held, according to Junior Mining Pro.
  • Moving quickly. Fieldwork started six days after the deal closed, and chief executive Oscar Mendoza has said he has spoken with a potential buyer for future production.
  • Professional money is watching. Singapore fund manager Ki-Un Park of Straits Invest has taken a position and said his fund would probably join Krait's next financing.

The Bales grades are historical and not yet confirmed by modern drilling under Canada's NI 43-101 rules, so the fieldwork now under way is the first real test. No government funding has been announced for Krait itself, and as with any early-stage explorer, results can move the share price sharply in either direction.

What we're watching

Further stockpile purchases and how the 2027 sourcing rules are enforced, antimony prices as China adjusts its export policy, and the first results from Bales. If Krait's fieldwork lands well, it will have turned a strong story into hard evidence at exactly the moment Washington is looking for new American supply.

General advice warning. This briefing is general information only. It does not take into account your objectives, financial situation or needs, and is not a recommendation to buy or sell any financial product. Read the full disclaimer.